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Objective: The aim of this research was to study the inﬂuence of female age on the cumulative live-birth
rate of fresh and subsequent frozen cycles using vitriﬁed blastocysts of the same cohort in hyper-
responders.
Materials and methods: This was a retrospective study of 1137 infertile women undergoing their ﬁrst
in vitro fertilization treatment between 2006 and 2013. The main outcome measure was cumulative live
births among the fresh and all vitriﬁed blastocyst transfers combined after the same stimulation cycle.
The results were also analyzed according to age (i.e., <35 years, 35e39 years, and 40 years).
Results: The mean number of retrieved oocytes was 19.9 ± 8.5 oocytes. The cumulative pregnancy rate
was 89.2% and the cumulative live-birth rate was 73.3%. The cumulative live-birth rate declined from
73.9% for women younger than 35 years old to 67.3% for women 35e39 years old to 57.9% for women 40
years or older.
Conclusion: Combined fresh and vitriﬁed blastocyst transfer cycles can result in a high cumulative live-
birth rate. The cumulative live-birth rates among older women are lower than the rates among younger
women when autologous oocytes are used.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
In the beginning of in vitro fertilization (IVF) treatment, all
available embryos were transferred because of the low success rate;
however, improvements in the clinical and laboratory aspects of IVF
have increased the pregnancy rate and the risk of multiple preg-
nancies. To prevent multiple pregnancies, fewer embryos are
transferred and the supernumerary embryos are cryopreserved for
potential future use [1,2].
After IVF, the cryopreservation of human embryos is more
important than ever for the cumulative pregnancy rate. In the past, Lee Women's Hospital, 263
bstetrics & Gynecology. Publishedfew years, the general success rates for frozenethawed embryo
transfers (FETs) have increased, and a recent systematic review
shows that FET results in signiﬁcantly higher ongoing pregnancy
rates, compared to fresh embryo transfer (ET) [3]. According to the
United States (U.S.) Centers for Disease Control and Prevention
(CDC; Atlanta, GA, USA) [4], which collects data on the success rates
of assisted reproductive technology (ART) among all American
fertility clinics, the live-birth rate in 2012 was 46.9% for fresh cycles
and 42.0% for FET cycles [4]. A recent review supports that FET re-
duces the risk of ovarian hyperstimulation syndrome and improves
the outcomes for the mother and the baby [5].
Consistent clinical outcomes similar to those from fresh trans-
fers have been reported after vitriﬁcation. A systematic review and
meta-analysis showed a signiﬁcantly higher ongoing pregnancy
rate with vitriﬁcation, compared to slow freezing [6]. The literatureby Elsevier Taiwan LLC. All rights reserved.
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blastocyst-stage embryos. A Cochrane review demonstrated that
live-birth rates can be optimized by performing fresh blastocyst
transfers, compared to cleavage stage ETs [7].
The success rate and live-birth rate of IVF demonstrate a similar
age-related decline in the chance of a natural pregnancy [8].
Patient-speciﬁc parameters such as maternal age can also impact
embryo development and competency [9]. Luke et al [10] report
that the delivery rates are lower among older women than among
younger women when autologous oocytes are used.
Recent publications have reported IVF success rates in cumula-
tive delivery rate per woman, and thus provide a more realistic
estimate that is applicable to individual couples [11,12]. This study
was designed to assess the inﬂuence of female age on the cumu-
lative live-birth rates of fresh cycles and subsequent frozen cycles
using vitriﬁed blastocysts of the same cohort.
Materials and methods
Patient selection
We performed a retrospective study of 1137 couples undergoing
their ﬁrst controlled ovarian stimulation for IVF at the LeeWomen's
Hospital in Taichung, Taiwan between September 2006 and August
2013. Eligibility inclusion criteria were: (1) a woman younger than
42 years old; (2) a woman undergoing her ﬁrst IVF or intra-
cytoplasmic sperm injection (ICSI) cycle; (3) a long ovulation in-
duction protocol; (4) ejaculated sperm origin; (5) blastocyst
transfer in the fresh cycle; and (6) vitriﬁed blastocyst transfer in the
frozen cycle. The exclusion criteria were (1) oocyte donation cycles;
(2) vitriﬁed oocytes cycles; (3) nonejaculated sperm; (4) two pro-
nucleate or cleavage ET; and (5) lack of a vitriﬁed blastocyst. Ethics
approval was obtained from the Institutional Review Board of
Chung Shan Medical University Hospital (Taichung, Taiwan). The
intention was to study the cumulative live-birth rates that utilized
vitriﬁed blastocysts and their fresh siblings from the same stimu-
lation cycle.
Stimulation cycle
Details of the stimulation cycle have been previously reported
[13]. In brief, the protocol beganwith daily subcutaneous injections
of leuprolide acetate (Lupron; Takeda Pharmaceutics, Konstantz,
Germany) 0.5 mg on Day 21 of the prestimulation cycle. On cycle
Days 3e7, gonadotropin (Gonal-F, 225 IU/day; Serono, Bari, Italy)
was administered subcutaneously. To stimulate follicular develop-
ment, the dose was then adjusted according to the ovarian
response. When two or more follicles reached a maximum diam-
eter of 18 mm, 10,000 IU human chorionic gonadotropin (hCG;
Profasi; Serono) was administered. Transvaginal oocyte retrieval
was performed 32e34 hours after the hCG injection. Fertilization
was performed by conventional insemination or by ICSI, depending
on the semen parameters. The standard of care throughout the
study period was blastocyst transfer. Fresh ET was performed with
the replacement of at most two blastocysts with the best quality.
Embryo cryopreservation and vitriﬁed ETs
Supernumerary blastocysts were cryopreserved with vitriﬁca-
tion. The details of the vitriﬁcation and thawing protocols have
been previously reported [14]. The vitriﬁed blastocysts were
thawed on the morning of the FET, and were discarded if more than
50% of the original blastomeres had degenerated on thawing. Fro-
zenethawed blastocysts were transferred in natural cycles in
ovulatory women or in hormone replacement cycles foranovulatory women. A maximum of two frozen blastocysts were
transferred in any one FET cycle. Patients failing to achieve a live-
birth after fresh ET went through cryopreserved cycles until all
vitriﬁed embryos were transferred or a live-birth was achieved.
Pregnancy outcome
A pregnancy test was performed 14 days after the transfer.
Pregnancy was deﬁned by a serum hCG concentration above 10 IU/
L. One week later, ultrasound examination was offered to pregnant
women to conﬁrm the intrauterine pregnancy. Live births were
deﬁned by the birth of at least one live infant. The cumulative live-
birth rate was the proportion of transfers that resulted in at least
one live birth, whether from the ﬁrst transfer attempt or subse-
quent transfers of the frozenethawed supernumerary blastocysts.
Statistical analysis
The primary outcome measure was the cumulative live-birth
rate among the fresh cycles and all FET cycles combined, after the
same stimulation cycle. Differences in the pregnancy rate and live-
birth rate between the age groups were analyzed using the Chi-
square test. Statistical analysis was performed using the Statistical
Program for Social Sciences, version 15.0 (SPSS Inc., Chicago, IL,
USA). A value of p < 0.05 was considered statistically signiﬁcant.
Results
Figure 1 shows the ﬂow chart of the enrollment process for the
patients. The characteristics of the study population are presented
in Table 1. The ﬁnal data set for analysis included 1137 womenwith
an initial fresh cycle (i.e., cycle 1). Among these women, 390
women did not become pregnant and underwent a ﬁrst frozen
cycle (i.e., cycle 2). Twenty-nine women did not become pregnant
in cycle 2 and underwent a second frozen cycle (i.e., cycle 3). The
clinical pregnancy rate per transfer was 65.7% in cycle 1, 64.1% in
cycle 2, and 56.8% in cycle 3. The cumulative pregnancy rate was
87.7% after two cycles (i.e., the fresh cycle and the ﬁrst frozen cycle)
and 89.2% after three cycles (i.e., the fresh cycle and two subsequent
frozen cycles; Table 2). The live-birth rate was 53.8% in cycle 1,
53.1% in cycle 2, and 48.3% in cycle 3. The cumulative live-birth rate
was 72.0% after two cycles and 73.3% after three cycles (Table 3).
The cumulative pregnancy rates among women after two cycles
decreased with age (<35 years, 88.5%; 35e39 years, 85.6%; and40
years, 84.2%; Table 4). The cumulative live-birth rates among the
women after two cycles signiﬁcantly decreased with age (<35
years, 73.9%; 35e39 years, 67.3%; and 40 years, 57.9%; p ¼ 0.038;
Table 5). The IVF/ET-related complications were multiple preg-
nancy and ovarian hyperstimulation syndrome. The estimated rates
of these complications were 36.7% and 2.8%, respectively.
Discussion
Our retrospective study shows that IVF-ICSI and vitriﬁed blas-
tocysts offer high cumulative pregnancy rates (89.2%) and cumu-
lative live-birth rates (72.3%) with the same cohort oocytes.
Optimization of stimulation protocols and laboratory techniques
has contributed to overall greater success rates and a greater
number of high-quality embryos to cryopreserve. The high cumu-
lative live-birth rates in this study can be explained by the effec-
tiveness of the blastocyst vitriﬁcation technique.
Embryo cryopreservation has decreased the number of fresh ETs
and maximized the effectiveness of the IVF cycle. However, there is
still a major debate concerning the best stage, protocol, and cryo-
protective additives to use. Cryopreservation of the remaining
IVF = in vitro fertilization.
Total number of IVF cycles (10,618)
Number of first IVF 
cycles (7433)
Number of other IVF cycles 
(3185)
Number of long protocol cycles
(4089)
Number of other protocol cycles 
(3344)
Number of fresh blastocyte transfer cycles
(1137)
Figure 1. A ﬂow chart of the enrollment process of the patients. IVF ¼ in vitro fertilization.
Table 1
Patient demographics and embryology data.
Total population (n ¼ 1137)
Agea (y) 32.7 ± 4.4
BMIa (kg/m2) 22.6 ± 3.1
Duration of infertilitya (y) 3.4 ± 2.6
Infertility factors
Male factor, n (%) 407 (35.8)
Tubal factor, n (%) 229 (20.1)
Endometriosis, n (%) 180 (15.8)
PCOS, n (%) 129 (11.4)
Multiple factors, n (%) 183 (16.1)
Unexplained factor, n (%) 9 (0.8)
No. of retrieved oocytesa 19.9 ± 8.5
No. of fertilized oocytesa 13.3 ± 5.7
No. of blastocystsa 7.8 ± 3.5
No. of transferred blastocystsa 2.4 ± 0.7
No. of vitriﬁed blastocystsa 4.0 ± 2.6
BMI ¼ body mass index; PCOS ¼ polycystic ovarian syndrome.
a The data are presented as mean ± standard deviation.
Table 2
Cumulative pregnancy rates after fresh and frozen embryo transfer.
Fresh cycle
(cycle 1)
1st frozen cycle
(cycle 2)
2nd frozen cycle
(cycle 3)
No. of ET cycles 1137 390 29
No. of pregnancies 747 250 17
Pregnancy ratea (%) 65.7 64.1 56.8
Cumulative pregnancy rate (%) d 87.7 89.2
No. of multiple pregnancies 428 126 17
Multiple pregnancy rate (%) 37.6 32.3 58.6
ET ¼ embryo transfer.
a There was no signiﬁcant differences between the three groups.
Table 3
Cumulative live-birth rates after fresh and frozen embryo transfer.
Fresh cycle
(cycle 1)
1st frozen cycle
(cycle 2)
2nd frozen cycle
(cycle 3)
No. of ET cycles 1137 390 29
No. of live births 612 207 14
Live-birth ratea (%) 53.8 53.1 48.3
Cumulative delivery rate (%) d 72.0 73.3
ET ¼ embryo transfer.
a There was no signiﬁcant differences between the three groups.
Table 4
Cumulative pregnancy rates of the different age groups after fresh and frozen em-
bryo transfer.
Age (y) No. of ET
cycles
Fresh cycle
(cycle 1)
1st frozen cycle
(cycle 2)
2nd frozen cycle
(cycle 3)
PR
pa
<35 840 PR (%) 66.3
(557/840)
65.7
(186/283)
66.7
(10/15)
0.983
CPR (%) d 88.5
(743/840)
89.6
(753/840)
35e39 278 PR (%) 64.0
(178/278)
60.0
(60/100)
50.0
(7/14)
0.478
CPR (%) d 85.6
(238/278)
88.1
(245/278)
40 19 PR (%) 63.2
(12/19)
57.1
(4/7)
d 0.780
CPR (%) d 84.2
(16/19)
d
CPR
p
0.411
CPR ¼ cumulative pregnancy rate; ET ¼ embryo transfer; PR ¼ pregnancy rate.
a The p value is based on the Chi-square test.
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Table 5
Cumulative live birth rates for different age groups after fresh and frozen embryo transfer.
Age (y) No. of ET cycles Fresh cycle
(cycle 1)
1st frozen cycle
(cycle 2)
2nd frozen cycle
(cycle 3)
LBR
pa
<35 840 LBR (%) 54.8
(460/840)
56.9
(161/283)
46.7
(7/15)
0.659
CLBR (%) d 73.9
(621/840)
74.8
(628/840)
35e39 278 LBR (%) 51.8
(144/278)
43.0
(43/100)
50.0
(7/14)
0.320
CLBR (%) d 67.3
(187/278)
69.8
(194/278)
40 19 LBR (%) 42.1
(8/19)
42.9
(3/7)
d 0.973
CLBR (%) d 57.9
(11/19)
d
CLBR
p
0.038
CLBR ¼ cumulative live-birth rate; ET ¼ embryo transfer; LBR ¼ live-birth rate.
a The p value is based on the Chi-square test.
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should always be encouraged for potential use in future frozen
cycles. A recent study shows that blastocyst transfer has a signiﬁ-
cantly higher cumulative pregnancy rate than a cleavage stage
transfer in women 35 years or older [15]. Utilization of these
blastocysts maximizes the cumulative pregnancy rate from a single
IVF cycle [10,16].
There is no consensus on the superiority of any cryopreser-
vation protocol. Two literature reviews and meta-analyses
showed a higher post-thaw survival rate for vitriﬁcation,
compared to slow freezing [17,18]. When evaluating the efﬁcacy
of vitriﬁcation versus slow cooling, it must be emphasized that
embryo survival is an important endpoint, but is insufﬁcient to
determine which method is actually superior in clinical practice
[19]. Therefore, the success of ART treatment should ultimately
be deﬁned by the live-birth rate when appraising the efﬁcacy of
vitriﬁcation versus slow freezing [19]. A recent population-based
cohort study showed that vitriﬁed blastocysts resulted in signif-
icantly higher live delivery rates, compared to slow-frozen blas-
tocysts [20]. In our study, all remaining blastocysts were
cryopreserved by vitriﬁcation.
The number of FET has increased in the past few years. The latest
results generated from European registers by the European Society
of Human Reproduction and Embryology demonstrate that embryo
cryotransfers account for 21% of IVF activity. The pregnancy rate per
thawing has increased since 2008 (19.3% in 2008, 20.9% in 2009,
and 20.3% in 2010); this improvement may be related to the
incorporation of vitriﬁcation in the embryology laboratory [21].
From 1997 to 2011 in the U.S., the number of FETs per initiated cycle
has increased from 20% to 34% (i.e., a 70% increase) for women
younger than 35 years [22]. The success rate after FET interestingly
is nearly equal to that of fresh ET. In this study, the live-birth rate
was 53.8% in the fresh cycles and 53.1% in the ﬁrst vitriﬁed cycles
with no signiﬁcant difference between the two cycles (Table 3). The
result is consistent with the report from the U.S. CDC on ART suc-
cess rates for all American fertility clinics in 2012 [4], which showed
a similar live-birth rate between the fresh cycle and the FET cycle
(46.9% vs. 42.0%, respectively).
Recent epidemiologic studies show an increased rate of adverse
perinatal outcomes for children of fresh IVF cycles, compared with
children of frozen ET cycles [23e26]. This increase does not occur in
the donor oocyte population, which suggests that it is the peri-
implantation environment created after superovulation that is
responsible for these changes [27]. Furthermore, some human data
demonstrate greater receptive endometrium in cycles withoutovarian stimulation, compared to cycles with stimulation [28e30].
Because of the aforementioned ﬁndings, some reports have hy-
pothesized a so-called “freeze-all strategy” that may increase the
success rates of IVF-ICSI treatment [5,22,27,31e35]. The outcomes
of existing randomized trials appear to favor the strategy of frozen
ET. However, high-quality randomized controlled trials should be
performed to determine which cryopreservation protocol is best
and whether a freeze-all strategy may completely abandon fresh
transfers.
In general, the cumulative live-birth rate after IVF is reportedly
between 45% and 55%. The quality and quantity of embryos are the
two most important predictors of a completed IVF/ICSI cycle (i.e.,
fresh plus cryopreserved embryos transferred from one stimulated
cycle) [36,37]. In addition, maternal age signiﬁcantly reduces the
cumulative live-birth rate [11]. Awoman's age is a negative factor if
she is 35e37 years old, and live-birth rates for IVF dramatically
decrease beyond the age of 40 years [16,38].
Our cumulative live-birth rate (74.8%) was higher in females
younger than 35 years, which is in agreement with previous pub-
lications [8,39]. In our study, the cumulative live-birth rates among
women after two cycles (i.e., fresh cycle and the ﬁrst frozen cycle)
decrease with age (<35 years, 73.9%; 35e39 years, 67.3%; and 40
years, 57.9%), which was consistent with a previous report that
demonstrated that live-birth rates are lower among older women
than among younger women when autologous oocytes are used
[10]. The low live-birth rate in women of advanced maternal age
resulted from the high risk of producing aneuploid embryos. Ac-
cording to our previous unpublished preimplantation genetic
screening data, the aneuploidy rate of embryos signiﬁcantly
increased from42.5% for womenyounger than 35 years old to 72.5%
for women 40 years or older.
Our improved cumulative live-birth rates could simply be a
result of improved technology [40]. It is therefore difﬁcult to
compare our results with earlier studies. However, a major
strength of this study is the use of a cohort of all women pre-
senting for their ﬁrst fresh IVF cycle, followed by a subsequent
frozen transfer utilizing blastocysts of the same cohort. When the
fresh cycle is unsuccessful, there is a higher likelihood that the
embryos capable of generating a viable pregnancy in the cohort
remain cryopreserved [41].
The limitation of this study is that the population of older
womenwas relatively small. In this study, we only enrolled women
younger than 42 years old who had undergone a blastocyst trans-
fer; there were consequently only 19 older women (40e42 years
old). Selection bias is therefore another limitation of this study.
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for women who underwent fresh and vitriﬁed blastocyst transfer
cycles and showed that the cumulative live-birth rates decrease
with age. The success rates after FET is nearly equal to the success
rates of fresh ETs. However, there is no clear choice that maximizes
the success rates for all patients at all centers. Therefore, individ-
ualized approaches remain appropriate.Conﬂict of interest
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